Logo

Hetero's Tocira (biosimilar- tocilizumab) Receives the DCGI's EUA for the Treatment of COVID-19 in Hospitalized Adults

Share this

Hetero's Tocira (biosimilar- tocilizumab) Receives the DCGI's EUA for the Treatment of COVID-19 in Hospitalized Adults

Shots:

  • DCGI has granted a EUA for tocilizumab in India for the treatment of COVID-19 in hospitalized adults who receives systemic corticosteroids and require supplemental oxygen- non-invasive or invasive mechanical ventilation- or ECMO
  • Hetero’s Tocira will be marketed by Hetero Healthcare in India & manufactured by Hetero Biologics
  • Tocilizumab (400mg/20ml) is the biosimilar referencing Roche’s Actemra/RoActemra and is expected to be available at the end of Sept’21

| Ref: Hetero | Image: Pharma Boardroom

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions